Efficacy and safety of single-inhaler triple therapy of glycopyrronium, formoterol and fluticasone in patients with COPD: a double-blind, randomised controlled trial

Sundeep Salvi, Akash Balki, Srikanth Krishnamurthy, Sagar Panchal, Saiprasad Patil, Rahul Kodgule, Hitesh Khandagale, Amol Pendse, Wen Wu, Shabbir Rangwala, Monika Tandon, Hanmant Barkate

Source: ERJ Open Res, 7 (3) 00255-2021; 10.1183/23120541.00255-2021
Journal Issue: July
Disease area: Airway diseases

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Sundeep Salvi, Akash Balki, Srikanth Krishnamurthy, Sagar Panchal, Saiprasad Patil, Rahul Kodgule, Hitesh Khandagale, Amol Pendse, Wen Wu, Shabbir Rangwala, Monika Tandon, Hanmant Barkate. Efficacy and safety of single-inhaler triple therapy of glycopyrronium, formoterol and fluticasone in patients with COPD: a double-blind, randomised controlled trial. ERJ Open Res, 7 (3) 00255-2021; 10.1183/23120541.00255-2021

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
A multi-centre doubleblind randomised study examining the clinical outcome of treatment of the first asthma exacerbation with salmeterol xinafoate/fluticasone propionate combination product versus prednisolone
Source: Eur Respir J 2003; 22: Suppl. 45, 287s
Year: 2003

Indacaterol once-daily improves dyspnoea in COPD patients: a 26-week placebo-controlled study with open-label tiotropium comparison
Source: Annual Congress 2009 - Next generation bronchodilators
Year: 2009


Efficacy and safety of once-daily single-inhaler triple therapy in patients with inadequately controlled asthma: the CAPTAIN trial
Source: Breathe, 17 (1) 1198; 10.1183/20734735.0279-2020
Year: 2021



Safety and tolerability of indacaterol once-daily in COPD patients versus placebo and tiotropium: a 26-week study
Source: Annual Congress 2009 - New bronchodilators
Year: 2009

Glycopyrrolate MDI demonstrates comparable efficacy and safety to tiotropium DPI in a randomized, double-blind, placebo-controlled phase 2b study in patients with COPD
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II
Year: 2011

INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD
Source: Eur Respir J 2014; 44: 1548-1556
Year: 2014



Efficacy and safety of as-needed corticosteroid plus fast or short-acting beta-agonists monotherapy in patients with mild asthma: a meta-analysis of randomised controlled trials.
Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma
Year: 2020

A randomised, open-label study of umeclidinium versus glycopyrronium in patients with COPD
Source: ERJ Open Res 2016: 00101-2015
Year: 2016



Evaluation of ICS/LABA combination therapy on respiratory function in patients with asthma: Open-label, randomized, cross-over trial.
Source: International Congress 2018 – New developments in the treatment of asthma
Year: 2018


Pharmacokinetic interaction of glycopyrronium bromide pMDI and formoterol pMDI: A randomized, open-label, single-dose, 4-way cross-over study
Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis
Year: 2015


Randomized, placebo-controlled study of asthmatic smokers treated with montelukast or mid-dose fluticasone
Source: Annual Congress 2011 - Asthma management and response
Year: 2011

Budesonide versus prednisone in acute wheezing: randomized double-blinded controlled placebo study
Source: Annual Congress 2008 - Treatment and outcome of childhood asthma: new perspectives
Year: 2008


Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison
Source: Eur Respir J 2011; 37: 273
Year: 2011



Bronchodilator therapy with indacaterol once-daily in COPD: a 52-week comparison with formoterol
Source: Annual Congress 2009 - Next generation bronchodilators
Year: 2009


Comparison of efficacy and safety of two HFA formulations of fluticasone propionate; a double-blind, randomised, multicentric, parallel group study in patients with persistent moderate asthma
Source: Annual Congress 2009 - New aspects of inhalation therapy
Year: 2009

Nasal beclomethasone plus loratadine in patients with rhinitis and concomitant asthma: prospective, randomized, placebo-controlled trial
Source: Eur Respir J 2007; 30: Suppl. 51, 547s
Year: 2007

Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial
Source: Virtual Congress 2021 – ALERT: bronchiectasis and COVID
Year: 2021



Long-term safety of twice-daily aclidinium bromide in COPD patients: A one-year, double-blind study
Source: Annual Congress 2012 - COPD treatments: efficacy and safety
Year: 2012

A double-blind, double-dummy, randomized study of beclomethasone/formoterol versus fluticasone/salmeterol in treatment of moderate to severe asthma in Taiwan
Source: Annual Congress 2013 –Asthma drugs: new findings
Year: 2013